

09/868885

Practitioner's Docket No. 55999 (46342)**CHAPTER II**

TRANSMITTAL LETTER
TO THE UNITED STATES ELECTED OFFICE (EO/US)
(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

<u>PCT/JP99/07199</u>	<u>22 December 1999</u>	<u>25 December 1998</u>
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED

USE OF PEPTIDE
TITLE OF INVENTION

TAKEDA CHEMICAL INDUSTRIES, LTD.
APPLICANTS

Hirokazu MATSUMOTO, Chieko KITADA and Shuji HINUMA
INVENTORS

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231
ATTENTION: EO/US

NOTE: *To avoid abandonment of the application, the applicant shall furnish to the USPTO, not later than 20 months from the priority date: (1) a copy of the international application, unless it has been previously communicated by the International Bureau or unless it was originally filed in the USPTO, and (2) the basic national fee (see 37 C.F.R. § 1.492(a)). The 30-month time limit may not be extended. 37 C.F.R. § 1.495.*

WARNING: *Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. § 1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. § 1.8*

NOTE. *Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).*

CERTIFICATION UNDER 37 C.F.R. § 1.10*

(Express Mail label number is mandatory.)
(Express Mail certification is optional)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date June 22, 2001, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL895436625US, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

(type or print name of person mailing paper)

Anne Marie Serrecchia

Anne Marie Serrecchia
Signature of person mailing paper

WARNING: *Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. § 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence*

***WARNING:** *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing 37 C.F.R. § 1.10(b)*

09/868885
531 Rec'd PCT 22 JUN 2001

"Since the filing of correspondence under § 110 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will be granted on petition." Notice of Oct 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:

- a. This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
- b. The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2. Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
[]*	TOTAL CLAIMS	- 20 =	0	x \$ 18.00 =	\$0
	INDEPENDENT CLAIMS	- 3 =	0	x \$ 78.00 =	\$0
	MULTIPLE DEPENDENT CLAIM(S) (if applicable)	+ \$260.00			\$0
BASIC FEE**	[] U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY				\$0.00
	Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO:				
	[] and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(2) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 CFR 1.492(a)(4))	\$100.00			
	[] and the above requirements are not met (37 CFR 1.492(a)(1))	\$690.00			
	[X] U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY				
	Where no international preliminary examination fee as set forth in § 1.482 has been paid to the USPTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO:				
	[] has been paid (37 CFR 1.492(a)(2))	\$710.00			
	[] has not been paid (37 CFR 1.492(a)(3))	\$1000.00			
	[X] where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5)).....	\$860.00			860.00
	Total of above Calculations				\$ 860.00
SMALL ENTITY	Reduction by ½ for filing by small entity, if applicable. Affidavit must be filed. (note 37 CFR 1.9, 1.27, 1.28)				- \$
				Subtotal	\$ 860.00
				Total National Fee	\$ 860.00
	Fee for recording the enclosed assignment document \$40.00 (37 CFR 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".				\$ 40.00
TOTAL				Total Fees enclosed	\$ 900.00

- i. A check in the amount of \$900.00 to cover the above fees is enclosed.
- ii. Please charge Account No. _____ in the amount of \$ _____.

A duplicate copy of this sheet is enclosed.

**WARNING: "To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: * * * (2) the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).

WARNING. If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date.

09/868885

531 Rec'd PCT 22 JUN 2001

Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.

3. A copy of the International application as filed (35 U.S.C. 371(c)(2)):

NOTE: Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment. "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

a. is transmitted herewith.
b. is not required, as the application was filed with the United States Receiving Office.
c. has been transmitted
i. by the International Bureau.
Date of mailing of the application (from form PCT/IB/308): 6 July 2000
ii. by applicant on
Date

4. A translation of the International application into the English language (35 U.S.C. 371(c)(2)):

a. is transmitted herewith.
b. is not required as the application was filed in English.
c. was previously transmitted by applicant on
Date
d. will follow.

5. Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3)):

NOTE: The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36

a. are transmitted herewith.
b. have been transmitted
i. by the International Bureau.
Date of mailing of the amendment (from form PCT/IB/308):
ii. by applicant on
Date
c. have not been transmitted as
i. applicant chose not to make amendments under PCT Article 19.
Date of mailing of Search Report (from form PCT/ISA/210):
ii. the time limit for the submission of amendments has not yet expired.

The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.

6. A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. 371(c)(3)):

a. is transmitted herewith.
b. is not required as the amendments were made in the English language.
c. has not been transmitted for reasons indicated at point 5(c) above.

097868005

531 Rec'd PCT/ 22 JUN 2001

7. A copy of the international examination report (PCT/IPEA/409)
[X] is transmitted herewith.
[] is not required as the application was filed with the United States Receiving Office.

8. [] Annex(es) to the international preliminary examination report
a. [] is/are transmitted herewith.
b. [] is/are not required as the application was filed with the United States Receiving Office.

9. [] A translation of the annexes to the international preliminary examination report
a. [] is transmitted herewith.
b. [] is not required as the annexes are in the English language.

10. An oath or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 U.S.C. 115
a. [] was previously submitted by applicant on Date
b. [X] is submitted herewith, and such oath or declaration
i. [X] is attached to the application.
ii. [] identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70.
iii. [] will follow.

Other document(s) or information included:

11. An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):
a. [X] is transmitted herewith.
b. [] has been transmitted by the International Bureau.
Date of mailing (from form PCT/IB/308):
c. [] is not required, as the application was searched by the United States International Searching Authority.
d. [] will be transmitted promptly upon request.
e. [] has been submitted by applicant on Date

12. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98:
a. [] is transmitted herewith.
Also transmitted herewith is/are:
[] Form PTO-1449 (PTO/SB/08A and 08B).
[] Copies of citations listed.
b. [X] will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
c. [] was previously submitted by applicant on Date

13. An assignment document is transmitted herewith for recording.

A separate [] "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or [X] FORM PTO 1595 is also attached.

Takeda Chemical Industries, Ltd.
1-1 Doshomachi 4-chome, Chuo-ku, Osaka-shi
Osaka 541-0045 Japan

14. Additional documents:

- a. Copy of request (PCT/RO/101)
- b. International Publication No. WO 00/38704
 - i. Specification, claims and drawing
 - ii. Front page only
- c. Preliminary amendment (37 C.F.R. § 1.121)
- d. Other

Form PCT/IB/301Form PCT/IB/304Form PCT/IB/332Form PCT/RO/105Form PCT/IPEA/408Form PCT/IPEA/416, PCT/IB/33815. The above checked items are being transmitted

- a. before 30 months from any claimed priority date.
- b. after 30 months.

16. Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant Takeda Chemical Industries, Ltd., namely:

in the PCT Japanese Receiving Office, a paper copy of the Sequence Listing on 22 December 1999.

17. Submitted herewith Computer Readable Form (Floppy Disk), of the paper copy submitted in the Japanese Receiving Office on 22 December 1999.**AUTHORIZATION TO CHARGE ADDITIONAL FEES**

WARNING: *Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.*

NOTE: *"A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).*

NOTE: *"Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).*

The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. **04-1105**.

37 C.F.R. 1.492(a)(1), (2), (3), and (4) (filing fees)

WARNING: *Because failure to pay the national fee within 30 months without extension (37 C.F.R. § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box*

37 C.F.R. 1.492(b), (c) and (d) (presentation of extra claim s)

097868 000

531 Rec'd PCT 22 JUN 2001

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

37 C.F.R. 1.17 (application processing fees)
 37 C.F.R. 1.17(a)(1)-(5)(extension fees pursuant to § 1.136(a)).
 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).



SIGNATURE OF PRACTITIONER

Reg. No.: 33,860

Peter F. Corless

(type or print name of practitioner)

Tel. No.: (617) 439-4444

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP

P.O. Box 9169

P.O. Address

Boston, MA 02209

Fax. No.: (617) 439-4170

Customer No.: 21874

170786

SPECIFICATION

Use of Peptide

TECHNICAL FIELD

The present invention relates to uses of physiologically active peptides. In particular, the present invention relates to oxytocin secretion regulators or the like comprising a ligand polypeptide for a G protein-coupled receptor protein (receptor).

BACKGROUND ART

Many hormones and neurotransmitters regulate biogenic functions through specific receptors present in cell membranes. Most such receptors transmit intracellular signals through the activity of coupled guanine nucleotide-binding proteins (G proteins). These receptors have a common structure with a 7 transmembrane region, and are thus referred to as G protein-coupled receptors or seven transmembrane receptors (7TMR).

Examples of such G protein-coupled receptor proteins include human receptor protein encoded by phGR3 (or GPR10) gene (*Genomics*, 29:335 (1995)) and its corresponding rat receptor protein UHR-1 (*Biochem. Biophys. Res. Commun.*) 209: 606 (1995)).

PrRP (*Nature*, 393:272-276 (1998)) is known as a physiologically active peptide that functions as a ligand for the aforementioned phGR3 and UHR-1.

PrRP has been found to have prolactin-releasing action specific to anterior pituitary hormone in *in vitro* pituitary cell culture systems (*Nature*, 393:272-276

(1998)), but other types of physiological action, particularly the effects on posterior pituitary hormone, remain unclear. The endogenous regulatory hormone that regulates oxytocin, a posterior pituitary hormone, is currently unknown.

DISCLOSURE OF THE INVENTION

As a result of extensive research to overcome the aforementioned drawbacks, the inventors first prepared two kinds of monoclonal antibodies specific to PrRP with different recognition sites, and prepared a highly sensitive system for assaying PrRP (sandwich-EIA system) (Japanese Patent Application H10-140293, and WO 99/60112). Studies of the tissue distribution of PrRP in rats using this system confirmed the presence of high concentrations of PrRP in the posterior pituitary gland in addition to high concentration distribution in the hypothalamus, etc., as reported in *Nature*, 393:272 (1998). This is assumed to be related to some effect of PrRP on posterior pituitary hormone secretion. The intraventricular administration of PrRP in rats was also found to result in elevated oxytocin concentration in blood, indicating that PrRP has a function in regulating the release of oxytocin.

Specifically, the present invention relates to:

(1) an oxytocin secretion regulator, comprising a ligand peptide, or salt thereof, for a G protein-coupled receptor protein;

(2) an oxytocin secretion regulator according to (1) above, wherein the ligand peptide, or salt thereof, for a G protein-coupled receptor protein is a polypeptide, or an amide or an ester or a salt thereof, containing an

amino acid sequence that is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 44;

(3) an oxytocin secretion regulator according to (2) above, wherein the amino acid sequence represented by SEQ ID NO: 44 is SEQ ID NO: 3, 18, or 32;

(4) an oxytocin secretion regulator according to (1) above, wherein the ligand peptide, or salt thereof, for a G protein-coupled receptor protein is a polypeptide, or an amide or an ester or a salt thereof, containing an amino acid sequence that is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 45;

(5) an oxytocin secretion regulator according to (4) above, wherein the amino acid sequence represented by SEQ ID NO: 45 is SEQ ID NO: 6, 21, or 35;

(6) an oxytocin secretion regulator according to (1) above, comprising an oxytocin secretion stimulator;

(7) an oxytocin secretion stimulator according to (6) above, comprising a drug for ameliorating, preventing, or treating uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced induced abortion, or lacteal retension;

(8) the use of a ligand peptide, or salt thereof, for a G protein-coupled receptor protein in order to regulate oxytocin secretion;

(9) the use of a ligand peptide, or salt thereof, for a G protein-coupled receptor protein in order to manufacture an oxytocin secretion regulator; and

(10) a method for regulating oxytocin secretion, characterized by administering a ligand peptide, or salt thereof, for a G protein-coupled receptor protein to mammals with a disease related to insufficient oxytocin secretion.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the content of PrRP (19P2-L31) in rat tissue; and

Figure 2 shows the changes in the oxytocin concentration in blood during the intraventricular administration of 10 nmol PrRP (19P2-L31) to rats.

BEST MODE FOR CARRYING OUT THE INVENTION

Abbreviations for bases, amino acids, and the like in the Specification and figures are based on the IUPAC-IUB Commission on Biochemical Nomenclature and on abbreviations common in the field. Examples are given below. Optical isomers of amino acids are the L form, unless otherwise specified.

DNA: deoxyribonucleic acid

cDNA: complementary deoxyribonucleic acid

A: adenine

T: thymine

G: guanine

C: cytosine

RNA: ribonucleic acid

mRNA: messenger ribonucleic acid

ATP: adenosine triphosphate

EDTA: ethylenediaminetetraacetic acid

SDS: sodium dodecylsulfate

EIA: enzyme immunoassay
 Gly or G: glycine
 Ala or A: alanine
 Val or V: valine
 Leu or L: leucine
 Ile or I: isoleucine
 Ser or S: serine
 Thr or T: threonine
 Cys or C: cysteine
 Met or M: methionine
 Glu or E: glutamic acid
 Asp or D: aspartic acid
 Lys or K: lysine
 Arg or R: arginine
 His or H: histidine
 Phe or F: phenylalanine
 Tyr or Y: tyrosine
 Trp or W: tryptophan
 Pro or P: proline
 Asn or N: asparagine
 Gln or Q: glutamine
 pGlu: pyroglutamic acid
 Me: methyl group
 Et: ethyl group
 Bu: butyl group
 Ph: phenyl group

Substituents, protective groups, and reagents used
 in the Specification are represented by the following
 symbols.

BHA: benzhydrylamine
 pMBHA: p-methylbenzhydrylamine
 Tos: p-toluenesulfonyl
 CHO: formyl
 HONB: N-hydroxy-5-norbornene-2,3-dicarboxyimide

OcHex: cyclohexyl ester
Bzl: benzyl group
Cl₂-Bzl: dichlorobenzyl group
Bom: benzyloxymethyl
Z: benzyloxycarbonyl
Br-Z: 2-bromobenzylloxycarbonyl group
Boc: t-butyloxycarbonyl group
DCM: dichloromethane
HOEt: 1-hydroxybenztriazole
DCC: N,N'-dicyclohexylcarbodiimide
TFA: trifluoroacetic acid
DIEA: diisopropylethylamine
Fmoc: N-9-fluorenylmethoxycarbonyl group
DNP: dinitrophenyl group
Bum: tertiary butoxymethyl group
Trt: trityl group

As used herein, "substantially the same" means that activity of the polypeptide (such as the ligand-receptor binding activity), oxytocin secretion-regulating action of the polypeptide (such as action in promoting or inhibiting oxytocin secretion), or the like is essentially the same. Therefore, "substantially the same" amino acid sequence means an amino acid sequence which may be mutated to the extent that activity of the polypeptide (such as the ligand-receptor binding activity), oxytocin secretion-regulating action of the polypeptide (such as action in promoting or inhibiting oxytocin secretion), or the like is essentially the same (the mutation produces no significant changes).

It is generally well known that mutations such as substitutions, deletions, or insertions (additions) of amino acids in a polypeptide sequence often do not bring about (major) significant changes in the physiological or chemical properties of polypeptides. Examples of such

substitutions include the substitution of an amino acid with another amino acid having similar properties. It is generally believed that the stronger the similarities between the amino acids that are exchanged, the fewer the differences in properties from the original polypeptide before the substitution as a result of the substitution.

Amino acids may be classified into the following classes, for example, on the basis of similarities in properties: (i) nonpolar (hydrophobic) amino acids such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (ii) polar (neutral) amino acids such as glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (iii) amino acids with a positive charge (basic) such as arginine, lysine, and histidine; and (iv) amino acids with a negative charge (acidic) such as aspartic acid and glutamic acid.

In the present Specification, substituents that are "substantially the same" as the target amino acid in the amino acid sequence are often selected, for example, from other amino acids with similar properties among the same class of amino acids.

In the present invention, polypeptides (mutant polypeptides) obtained as a result of mutation in the amino acid sequence, such as substitutions, deletions, or insertions that bring about (major) significant changes in the physiological or chemical characteristics of the original (unmutated) polypeptide may be regarded as being substantially the same as the original (unmutated) polypeptide which lacks such mutations, and the amino acid sequence of the mutated polypeptide may be regarded as being substantially the same as the amino acid sequence of the original (unmutated) polypeptide.

The constitutive amino acids of the polypeptides in the present invention include both the D and L forms, but the L form is preferred unless otherwise specified.

Polypeptides in the present invention are ligand polypeptides, or their amides or esters or salts, for G protein-coupled receptor proteins, specifically, ligand polypeptides, or their amides or esters or salts, which are capable of binding to G protein-coupled receptor protein. Specific examples include polypeptides or their amides or esters or salts (henceforth sometimes abbreviated as ligand polypeptides or polypeptides) containing an amino acid sequence that is the same as or substantially the same as an amino acid sequence represented by SEQ ID NO: 44 or 45.

As used here, G protein-coupled receptor protein is a receptor protein having a common structure with a 7 cell transmembrane region, which often transmits intracellular signals through the activation of a coupled guanine nucleotide-binding protein.

Preferred examples of the amino acid sequence represented by SEQ ID NO: 44 include amino acid sequences represented by SEQ ID NOS: 3, 18, and 32. The amino acid sequence represented by SEQ ID NO: 32 is particularly preferred.

Preferred examples of the amino acid sequence represented by SEQ ID NO: 45 include amino acid sequences represented by SEQ ID NOS: 6, 21, and 35. The amino acid sequence represented by SEQ ID NO: 35 is particularly preferred.

Examples of the polypeptides in the present invention are those derived from any tissue (e.g., the

pituitary, pancreas, brain, kidneys, liver, gonads, thyroid, gall bladder, bone marrow, adrenal gland, skin, muscle, lungs, digestive tract, blood vessels, and heart), cells, and the like from humans and warm-blooded animals (guinea pigs, rats, mice, pigs, goats, cows, monkeys, etc.). Specific examples include those with an amino acid sequence that is the same as or substantially the same as an amino acid sequence represented by SEQ ID NO: 44 or 45, and preferably those with an amino acid sequence the same as or substantially the same as an amino acid sequence represented by SEQ ID NO: 3, 18, or 32, or 6, 21, or 35.

Examples of the ligand polypeptides in the present invention include, in addition to polypeptides with an amino acid sequence represented by SEQ ID NO: 44 or 45, and preferably 3, 18, or 32, or 6, 21, or 35, any polypeptide with an amino acid sequence having about 50 to 99.9% (preferably 70 to 99.9%, even more preferably 80 to 99.9%, and especially 90 to 99.9%) homology with an amino acid sequence represented by SEQ ID NO: 44 or 45, and preferably 3, 18, or 32, or 6, 21, or 35, and more preferably polypeptides having activity substantially the same as that of polypeptides with an amino acid sequence represented by SEQ ID NO: 3, 18, or 32, or 6, 21, or 35. Examples of the activity include the activity of ligand polypeptides, such as receptor-binding activity and signal transduction activity. "Substantially the same" activity means that properties such as receptor-binding activity are the same. The receptor-binding activity may therefore be slightly stronger or weaker. Differences in the molecular weight of the ligand polypeptides are not a problem. Although substantially the same peptides from the same genus of humans or warm-blooded animals may have differences based on amino acid sequences that are not intrinsic to the peptide but are due to differences in a

given species (such as individual variation), such peptides with non-intrinsic amino acid sequence-based differences are included in the polypeptides of the present invention.

The manufacturing method and uses of the ligand polypeptides of the present invention are described in further detail below.

Specific examples of the ligand polypeptides in the present invention include polypeptides from rats, cows, humans, or mice, with an amino acid sequence represented by SEQ ID NO: 44 or 45 (in SEQ ID NO: 44, the Xaa at 3 is Thr or Ala, the Xaa at 5 is Arg or Gln, the Xaa at 10 is Ile or Thr, the Xaa at 21 is Thr or Ala, and the Xaa at 22 is Gly or Ser; and in SEQ ID NO: 45, the Xaa at 10 is Thr or Ala, and the Xaa at 11 is Gly or Ser).

The ligand polypeptides of the present invention include polypeptides, or their amides or esters or salts, containing:

(i) amino acid sequences in which 1 to 15, preferably 1 to 10, and even more preferably 1 to 5 amino acids in the amino acid sequence represented by SEQ ID NO: 44 are substituted by other amino acids;

(ii) amino acid sequences in which 1 to 23, preferably 1 to 16, and even more preferably 1 to 11 amino acids in the amino acid sequence represented by SEQ ID NO: 44 are deleted;

(iii) amino acid sequences in which 1 to 15, preferably 1 to 10, and even more preferably 1 to 5 amino acids are added to (inserted into) the amino acid sequence represented by SEQ ID NO: 44; and

(iv) amino acid sequences in which constitutive amino acids (particularly the side chains) of polypeptides in (i), (ii), or (iii) have been modified.

The ligand polypeptides of the present invention also include polypeptides, or their amides or esters or salts, containing:

(v) amino acid sequences in which 1 to 10, and preferably 1 to 5 amino acids in the amino acid sequence represented by SEQ ID NO: 45 are substituted by other amino acids;

(vi) amino acid sequences in which 1 to 10, and preferably 1 to 5 amino acids in the amino acid sequence represented by SEQ ID NO: 45 are deleted;

(vii) amino acid sequences in which 1 to 10, and preferably 1 to 5 amino acids are added to (inserted into) the amino acid sequence represented by SEQ ID NO: 45; and

(viii) amino acid sequences in which constitutive amino acids (particularly the side chains) of polypeptides in (v), (vi), or (vii) have been modified.

The substitutions, deletions, addition, modifications, and the like to the amino acid sequences as described in (i) through (viii) above can be brought about intentionally or incidentally to allow the ligand polypeptides of the present invention to be mutated (changed) into ligand polypeptides that are stable against heat or protease, or highly active ligand polypeptides in which the inherent physiological activity of ligand polypeptides has been enhanced. The ligand

polypeptides or amides or esters thereof, or salts thereof according to the present invention include these mutated ligand polypeptides.

In accordance with the usual procedure for designating peptides, the left terminal in the present Specification is referred to as the N terminal (amino terminal), and the right terminal is referred to as the C terminal (carboxyl terminal).

Examples of modifications to the constitutive amino acids in the polypeptides of the present invention include the conversion of Gln to pyroglutamic acid upon the in vivo cleavage of the N terminal side of Gln.

The α -carboxyl group of C terminal amino acid residues of polypeptides in the present invention, such as polypeptides represented by SEQ ID NO: 44 or 45, is usually a carboxyl group (-COOH) or carboxylate (-COO $^-$), but the carboxyl groups of the C terminal amino acid residues may also be an amide (-CONH $_2$) or ester (-COOR). Examples of R in esters represented by -COOR include C₁₋₆ alkyl groups such as methyl, ethyl, n-propyl, isopropyl, or n-butyl, C₃₋₈ cycloalkyl groups such as cyclopentyl and cyclohexyl, C₆₋₁₂ aryl groups such as phenyl and α -naphthyl, phenyl-C₁₋₂ alkyls such as benzyl and phenethyl, or α -naphthyl-C₁₋₂ alkyls such as α -naphthylmethyl and other such C₇₋₁₄ aralkyl groups, as well as pivaloyloxymethyl groups which are commonly used as oral esters.

The polypeptides of the present invention, such as polypeptides represented by SEQ ID NO: 44 or 45, also include polypeptides which have carboxyl group or carboxylate in addition to those in the C terminal, where such groups are amidated or esterified. Examples of

esters in such cases are the same as the esters of the aforementioned C terminal amino acid residues.

Particularly desirable ligand polypeptides in the present invention include peptides in which the carboxyl groups of the C terminal amino acid residues are amides. Preferred examples include polypeptides in which the carboxyl groups of the C terminal amino acid residues in polypeptides having an amino acid sequence represented by SEQ ID NO: 3, 6, 18, 21, 32, or 35 are amides.

Although salts with physiologically acceptable bases (such as alkali metals) or acids (organic or inorganic acids) may be used as salts of the polypeptide in the present invention, the physiologically acceptable salts with acids are particularly preferred. Examples of such salts include salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, and sulfuric acid) or with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid).

The ligand polypeptides of the present invention can be manufactured by (i) techniques for purifying polypeptides from human or warm-blooded animal tissue or cells, or (ii) publicly known synthesis method of polypeptide. They can also be manufactured by (iii) techniques for culturing transformants containing the DNA encoding such polypeptides (to be described later).

(i) When the ligand peptide is manufactured from human or warm-blooded animal tissue or cells, the human or warm-blooded animal tissue or cells should be homogenized and then extracted with acid or the like, and the extract should be purified and isolated in the

combination of chromatography such as reverse phase chromatography, ion exchange chromatography, and affinity chromatography.

(ii) The ligand peptide can be manufactured by polypeptide synthesis techniques that are publicly known. Peptides may be synthesized by either solid phase synthesis or liquid phase synthesis, for example. That is, partial peptides or amino acids capable of constructing the ligand polypeptide are condensed with the remainder, and protective groups are eliminated when the product has protective groups, so as to manufacture the target peptide. The following methods in (1) through (5) are publicly known methods for condensation and the removal of protective groups.

(1) M. Bodanszky and M.A. Ondetti, *Peptide Synthesis*, Interscience Publishers, New York (1966)

(2) Schroeder and Luebke, *The Peptide*, Academic Press, New York (1965)

(3) Nobuo Izumiya et al, *Peptide Synthesis Fundamentals and Tests*, Maruzen (1975)

(4) Jimei Yashima and Toshihira Kashiwahara, *Basic Biochemical Tests*, Vol. 1, Protein Chemistry IV, 205 (1977)

(5) *Development of Medical Drugs*, Vol. 14, *Peptide Synthesis*, Hirokawa Shoten, Ed. Jimei Yashima

The following is a specific example of the synthesis of the ligand polypeptide in (ii) above.

Commercially available resins for peptide synthesis, which are suitable for amide formation can be used to synthesize amide forms of the ligand peptides. Examples of such resins include chloromethyl resins, hydroxymethyl resins, benzhydrylamine resins, aminomethyl resins, 4-benzyloxybenzyl alcohol resins, 4-methylbenzhydrylamine resins, PAM resins, 4-hydroxymethyl methylphenyl acetamide methyl resins, polyacrylamide resins, 4-(2',4'-dimethoxyphenyl-hydroxymethyl)phenoxy resins, and 4-(2',4'-dimethoxyphenyl-Fmoc aminoethyl)phenoxy resins. Such resins can be used for the condensation of amino acids with suitably protected side chain functional groups and α -amino groups on resin in accordance with various methods of condensation that are publicly known as befits the sequence of the intended peptide. After the reaction, the peptide is excised from the resin, the various protective groups are removed, and the target polypeptide can be obtained. Although various activating reagents that can be used in peptide synthesis may be used for the condensation of such protected amino acids, carbodiimides are particularly preferred. Examples of carbodiimides include DCC, N,N'-diisopropylcarbodiimide, and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide.

For activation with the above, racemization inhibitors (e.g., HOBT) and protected amino acids can be added directly to the resin, or they can be added in the form of corresponding acid anhydrides or HOBT esters or HOOBT esters to the resin after the activation of the protected amino acids. Solvents which are used for the condensation with resins or the activation of protected amino acids can be suitably selected from solvents which are publicly known to be capable of being used in peptide condensation. Examples of the solvents include acid amides such as N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone, halogenated

hydrocarbons such as methylene chloride and chloroform, alcohol such as trifluoroethanol, sulfoxides such as dimethylsulfoxide, tertiary amines such as pyridine, ethers such as dioxane and tetrahydrofuran, nitriles such as acetonitrile and propionitrile, esters such as methyl acetate and ethyl acetate, and suitable mixtures thereof. The reaction temperature of said reaction can be suitably selected from within the usable range in the publicly known reaction of the formation of peptide bonds, which is usually about -20 to 50°C. The activated amino acid derivatives are usually used in an excess amount of 1.5 to 4 times. The degree to which condensation has been achieved can be determined using a publicly known ninhydrin reaction. When such tests reveal insufficient condensation, the condensation is repeated without removing the protective groups until sufficient condensation has been achieved. When repeated reaction fails to provide sufficient condensation, acetic anhydride or acetyl imidazole may be used for the acetylation of the unreacted amino acids to avoid influencing subsequent reactions.

Examples of protective groups for the amino groups of amino acids as starting material in peptide synthesis include Z, Boc, tert-amyoxy carbonyl, isobornyloxy carbonyl, 4-methoxybenzyloxy carbonyl, Cl-Z, Br-Z, adamantyloxy carbonyl, trifluoroacetyl, phthalyl, formyl, 2-nitrophenylsulfenyl, diphenylphosphinothioyl, and Fmoc. Examples of protective groups for carboxyl groups include the aforementioned C₁₋₆ alkyl groups, C₃₋₈ cycloalkyl groups, C₇₋₁₄ aralkyl groups, 2-adamantyl, 4-nitrobenzyl, 4-methoxybenzyl, 4-chlorobenzyl, phenacyl groups, and benzyl oxy carbonyl hydrazide, tert-butoxycarbonyl hydrazide, and tritylhydrazide.

The hydroxyl groups of serine and threonine can be protected, for example, by esterification or etherification. Examples of groups that are suitable for esterification include lower (C₁₋₆) alkanoyl groups such as acetyl, alloyl groups such as benzoyl, and carbon-derived groups such as benzyloxycarbonyl and ethoxycarbonyl. Examples of groups that are suitable for etherification include benzyl, tetrahydropyranyl, and tert-butyl groups.

Examples of protective groups for phenolic hydroxyl groups of tyrosine include Bzl, Cl₂-Bzl, 2-nitrobenzyl, Br-Z, and tert-butyl.

Examples of protective groups for imidazoles of histidine include Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum, Boc, Trt, and Fmoc.

Examples of ligand polypeptides in the present invention include any peptides which have a mutated amino acid sequence, provided that the oxytocin-regulating function is the same as that of polypeptides having an amino acid sequence that is the same as or substantially the same as the amino acid sequence represented by SEQ ID NO: 44 or 45. Examples of such peptides include peptides with an amino acid sequence in which 1 to 20 amino acids have been deleted from a peptide having an amino acid sequence represented by SEQ ID NO: 44. Specific examples include (a) a peptide with an amino acid sequence from 2 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (b) a peptide with an amino acid sequence from 3 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (c) a peptide with an amino acid sequence from 4 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (d) a peptide with an amino acid sequence from 5

to 31 of the amino acid sequence represented by SEQ ID NO: 44; (e) a peptide with an amino acid sequence from 6 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (f) a peptide with an amino acid sequence from 7 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (g) a peptide with an amino acid sequence from 8 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (h) a peptide with an amino acid sequence from 9 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (i) a peptide with an amino acid sequence from 10 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (j) a peptide with an amino acid sequence from 11 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (k) a peptide with an amino acid sequence from 12 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (l) a peptide with an amino acid sequence from 13 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (m) a peptide with an amino acid sequence from 14 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (n) a peptide with an amino acid sequence from 15 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (o) a peptide with an amino acid sequence from 16 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (p) a peptide with an amino acid sequence from 17 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (q) a peptide with an amino acid sequence from 18 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (r) a peptide with an amino acid sequence from 19 to 31 of the amino acid sequence represented by SEQ ID NO: 44; (s) a peptide with an amino acid sequence from 20 to 31 of the amino acid sequence represented by SEQ ID NO: 44; and (t) a peptide with an amino acid sequence from 21 to 31 of the amino acid sequence represented by SEQ ID NO: 44.

SEQ ID NOS: 3, 18, and 32, which are preferred examples of the amino acid sequence represented by SEQ ID NO: 44 include the examples given for the amino acid sequence represented by SEQ ID NO: 44.

Examples also include peptides with an amino acid sequence in which 1 to 10 amino acids have been deleted from a peptide having an amino acid sequence represented by SEQ ID NO: 45. Specific examples include (a) a peptide with an amino acid sequence from 2 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (b) a peptide with an amino acid sequence from 3 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (c) a peptide with an amino acid sequence from 4 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (d) a peptide with an amino acid sequence from 5 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (e) a peptide with an amino acid sequence from 6 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (f) a peptide with an amino acid sequence from 7 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (g) a peptide with an amino acid sequence from 8 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (h) a peptide with an amino acid sequence from 9 to 20 of the amino acid sequence represented by SEQ ID NO: 45; (i) a peptide with an amino acid sequence from 10 to 20 of the amino acid sequence represented by SEQ ID NO: 45; and (j) a peptide with an amino acid sequence from 11 to 20 of the amino acid sequence represented by SEQ ID NO: 45.

SEQ ID NOS: 6, 21, and 35 which are preferred examples of the amino acid sequence represented by SEQ ID NO: 45 include the examples given for the amino acid sequence represented by SEQ ID NO: 45.

The ligand polypeptides of the present invention may also be in the form of fused proteins with other proteins (such as publicly known proteins with well known functions or properties).

Examples of DNA encoding the ligand polypeptides in the present invention include any DNA containing a base sequence encoding a polypeptide with an amino acid sequence that is the same as or substantially the same as the amino acid sequence represented by SEQ ID NO: 44 or 45 in the present invention. The DNA can be any of genomic DNA, a genomic DNA library, cDNA derived from tissue or cell, cDNA library derived from tissue or cell, or synthetic DNA. Vectors used for libraries can be any of bacteriophages, plasmids, cosmids, phagimids, or the like. RNA fractions prepared from tissue and cells can be used for direct amplification by RT-PCR (reverse transcription PCR).

Specifically, DNA having a base sequence represented by SEQ ID NO: 2 may be used as the DNA encoding rat whole brain or bovine hypothalamus derived polypeptides having an amino acid sequence represented by SEQ ID NO: 1 or 15.

The R at 129 in SEQ ID NO: 2 is G or A, and the Y at 179 and 240 are C or T. When the Y at 179 is C, the sequence codes for the amino acid sequence represented by SEQ ID NO: 1. When the Y at 179 is T, the sequence codes for the amino acid sequence represented by SEQ ID NO: 15.

DNA having a base sequence represented by SEQ ID NOS: 9, 10, 11, 12, 13, or 14 may be used as the DNA encoding bovine polypeptides with an amino acid sequence represented by SEQ ID NOS: 3, 4, 5, 6, 7, or 8.

The R at 63 in SEQ ID NOS: 9, 10, 11, 12, 13, and 14, and the R at 29 in SEQ ID NOS: 12, 13, 14 are G or A.

DNA having a base sequence represented by SEQ ID NOS: 17, 24, 25, 26, 17, 28, or 29 may be used as the DNA encoding rat polypeptides represented by SEQ ID NOS: 8, 18, 19, 20, 21, 22, or 23.

DNA having a base sequence represented by SEQ ID NOS: 31, 38, 39, 40, 41, 42, or 43 may be used as the DNA encoding human polypeptides represented by SEQ ID NOS: 30, 32, 33, 34, 35, 36, or 37.

As DNA probe, it is preferable to use DNA fragments containing part of the base sequence, such as from 6 to 90 (preferably 6 to 60, more preferably from 9 to 30, and even more preferably from 12 to 30), of the DNA encoding a bovine polypeptide with an amino acid sequence represented by SEQ ID NO: 1 or 15 in the present invention, a rat polypeptide with an amino acid sequence represented by SEQ ID NO: 16, or a human polypeptide with an amino acid sequence represented by SEQ ID NO: 30.

(iii) DNA encoding polypeptides in the present invention can be manufactured by the following genetic engineering techniques.

DNA fully encoding the polypeptides of the present invention should be cloned in the following manner. That is, (1) DNA having a partial base sequence for the polypeptide of interest is synthesized for use as a primer in PCR to amplify DNA fully encoding the polypeptide, or (2) cDNA, genomic DNA, or a DNA library obtained upon the insertion of such DNA fragments into a suitable vector is selected by hybridization with labeled material using synthetic DNA or DNA fragments having part

or all of the regions of the ligand polypeptide. The hybridization may be undertaken in accordance with techniques such as that in *Molecular Cloning* (2nd ed. J. Sambrook et al., Cold Spring Harbor Lab. Press (1989)). Commercially available DNA libraries should be used in accordance with the method described in the protocol.

Cloned polypeptide-encoding DNA may be used as such or after digestion with suitable restriction enzymes or after the addition of linker DNA. The DNA may have ATG as the translation start codon on the 5' terminal side, and TAA, TGA, or TAG as the stop codon on the 3' terminal side. The translation start and stop codons can be added using suitable synthetic DNA adapters.

Expression vectors containing DNA with a base sequence encoding such polypeptides can be manufactured by (1) excising target DNA fragments from the DNA containing the DNA encoding a polypeptide of the present invention, and (2) ligating the DNA fragments downstream of a promoter in a suitable expression vector, which is publicly known.

Examples of the vectors include *E. coli* plasmids (such as pBR322, pBR325, pUC12, and pUC13), *Bacillus subtilis* plasmids (such as pUB110, pTP5, and pC194), yeast plasmids (such as pSH19 and pSH15), bacteriophages such as λ -phages, and animal viruses such as retroviruses, vaccinia viruses, and baculoviruses. Examples of promoters include any promoters suitably functioning in the host used to express the gene encoding the target polypeptide.

Examples of promoters for when the host is *E. coli* during transformation include the trp promoter, lac promoter, recA promoter, λ PL promoter, and lpp promoter.

Examples for *Bacillus* hosts include the SPO1 promoter, SPO2 promoter, and penP promoter. Examples for yeast hosts include the PHO5 promoter, PGK promoter, GAP promoter, and ADH promoter. Examples for animal cell preferably include the SV40-derived promoters, retrovirus promoters, metallothionein promoters, heat shock promoters, cytomegalovirus promoters, and SRα promoters. The use of an enhancer is preferred for more efficient expression of the gene encoding the target polypeptide.

A signal sequence suitable for the host may be added as necessary to the N terminal side of the polypeptide or partial peptide. Preferred examples for *E. coli* hosts include alkaline phosphatase signal sequence and OmpA signal sequence. Preferred examples for subtilisin hosts include α-amylase signal sequence and subtilisin signal sequence. Preferred examples for yeast hosts include mating factor α signal sequence and invertase signal sequence. Preferred examples for animal cell hosts include insulin signal sequence, α-interferon signal sequence, and antibody molecule signal sequence. Vectors containing the DNA encoding the polypeptide or partial peptide constructed in this manner are used to manufacture transformants.

Hosts which can be used in transformation include, for example, *E. coli*, *Bacillus*, yeasts, insects, and animal cells.

Examples of *E. coli* include *E. coli* K12-DH1 (*Proc. Natl. Acad. Sci. USA*, 60:160 (1968)), JM103 (*Nucleic Acids Research*, 9:309 (1981)), JA221 (*Journal of Molecular Biology*, 120:517 (1978)), HB101 (*Journal of Molecular Biology*, 41:459 (1969)), and C600 (*Genetics*, 39:440 (1954)).

Specific examples of *Bacillus* include *Bacillus subtilis* MI114 (*Gene*, 24:255 (1983)), and 207-21 (*Journal of Biochemistry*, 95:87 (1984)).

Examples of yeasts include *Saccharomyces cerevisiae* AH22, AH22R, NA87-11A, DKD-5D, and 20B-12.

Examples of insects include silkworm larvae (Maeda et al., *Nature*, 315:592 (1985)).

Examples of animal cells include monkey COS-7 cells, Vero cells, Chinese hamster cells CHO, DHFR gene-deficient Chinese hamster cells CHO (dhfr⁻CHO cells), mouse L cells, mouse myeloma cells, and human FL cells.

E. coli can be transformed, for example, by a method such as that in *Proc. Natl. Acad. Sci. USA*, 69:2110 (1972) or *Gene*, 17:107 (1982).

Bacillus can be transformed, for example, by a method such as that in *Molecular & General Genetics*, 168:111 (1979).

Yeasts can be transformed, for example, by a method such as that in *Proc. Natl. Acad. Sci. USA*, 75:1929 (1978).

Insect cells can be transformed, for example, by a method such as that in *Bio/Technology*, 6:47 (1988).

Animal cells can be transformed, for example, by a method such as that in *Virology*, 52:456 (1973).

As described above, transformants which have been transformed with expression vectors containing DNA encoding polypeptides can be obtained.

When culturing transformants with *E. coli* or *Bacillus* hosts, liquid media are preferred for the culture, and should be prepared in such a way as to contain carbon sources, nitrogen sources, inorganic material, and other materials necessary for the growth of the transformants. The carbon sources include glucose, dextrins, soluble starches, and sucrose, and the nitrogen sources include inorganic or organic substances such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, soybean cake, and potato extract. Examples of inorganic materials include calcium chloride, sodium dihydrogen phosphate, and magnesium chloride. Yeast extracts, vitamins, growth stimulating factors, and the like may also be added to the medium as necessary. The medium pH should be a pH at which transformants grow, but the pH should preferably be about 5 to 8.

A preferred media for culturing *E. coli* is M9 medium containing glucose and casamino acid (Miller, *Journal of Experiments in Molecular Genetics*, pp. 431, Cold Spring Harbor Laboratory, New York (1972)). A chemical such as 3 β -indoleacrylic acid can be added to enhance the promoter as necessary. In cases where the host is *E. coli*, the culture usually takes about 3 to 24 hours at about 15 to 43°C. The culture can be aerated or stirred as necessary.

In cases where the host is *Bacillus*, the culture usually takes about 6 to 24 hours at about 30 to 40°C. The culture can be aerated or stirred as necessary.

Examples of media for the culture of transformants with yeast hosts include Burkholder minimum medium (K.L. Bostian et al., *Proc. Natl. Acad. Sci. USA*, Vol. 77, p. 4505 (1980), and SD medium containing 0.5% casamino acid

(G.A. Bitter et al., *Proc. Natl. Acad. Sci. USA*, Vol. 81, p. 5330 (1984).

The medium pH should be adjusted to about 5 to 8. The culture usually takes about 24 to 72 hours at about 20 to 35°C. The culture can be aerated or stirred as necessary.

Examples of media for the culture of transformants with insect hosts include Grace's Insect Medium (T.C.C. Grace, *Nature*, 195:788 (1962) suitably supplemented with additives such as 10% inactivated bovine serum. The medium pH should be adjusted to about 6.2 to 6.4. The culture usually takes about 3 to 5 days at about 27°C. The culture can be aerated or stirred as necessary.

Examples of media for the culture of transformants with animal cell hosts include MEM medium containing about 5 to 20% fetal calf serum (*Science*, 122:501 (1952)), DMEM medium (*Virology*, 8:396 (1959)), RPMI 1640 medium (*The Journal of the American Medical Association*, 199:519 (1967)), and 199 medium (*Proceedings of the Society for Biological Medicine*, 73:1 (1950)). The pH should be about 6 to 8. The culture usually takes about 15 to 60 hours at about 30 to 40°C. The culture can be aerated or stirred as necessary.

Polypeptides can be isolated and purified from the aforementioned cultures (culture broth and cultured bacterial cells or cultured cells) in the following manner, for example.

When polypeptides accumulate in cultured bacterial cells or cultured cells, the bacterial cells or cells are collected by a publicly known method following the

culture and are suspended in a suitable buffer, they are disrupted by publicly known ultrasonication, lysozyme treatment and/or by freezing and thawing, etc., and the target polypeptide or partial peptide is then obtained in the form of a crude extract by publicly known methods such as centrifugation, filtration or the like. The buffer may also contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 (registered trademark (TM) by Wako Pure Chemicals).

When the polypeptides are secreted into the culture, the bacterial cells or cells are separated from the supernatant by a publicly known method after the completion of the culture, and the polypeptides can be obtained as the supernatant.

The polypeptides of the present invention contained in the extract or culture supernatant obtained can be purified by a suitable combination of publicly known methods for isolation and purification. Examples of such publicly known methods for isolation and purification include 1) methods featuring the use of the degree of dissolution such as solvent precipitation or salting out, 2) methods primarily making use of differences in molecular weight such as dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis, 3) methods making use of differences in charge such as ion exchange chromatography, 4) methods making use of specific affinity such as affinity chromatography, 5) methods making use of hydrophobic differences such as reverse phase HPLC, and 6) methods making use of differences in isoelectric point, such as isoelectric point electrophoresis and chromatofocusing.

When the polypeptide is obtained in free form, it can be converted to a salt by a publicly known method or a modification thereof. Alternatively, when it is obtained in the form of a salt, it can be converted to free form or another salt by a publicly known method or a modification thereof.

Polypeptides can be modified as desired through the action of suitable protein-modifying enzymes in accordance with a publicly method before or after purification, or the sequence of the polypeptide can be partially removed. Examples of the protein-modifying enzymes include trypsin, chymotrypsin, arginylendopeptidase, protein kinase, and glycosidase. The activity of the resulting mutant polypeptides can be determined by enzyme immunoassay or the like using specific antibodies or receptor-binding tests.

The ligand polypeptides of the present invention have regulating action in oxytocin secretion, that is, action in promoting or inhibiting oxytocin secretion. As will become apparent in the following examples, the ligand polypeptides of the present invention have action in promoting oxytocin secretion, and can thus be used as a prophylactic or remedy for various diseases related to insufficient oxytocin secretion. The ligand polypeptides of the present invention also have strong affinity for receptor proteins, and thus have action in inhibiting oxytocin secretion as a result of desensitization with regard to oxytocin secretion when the dosage is increased. The ligand polypeptides can therefore also be used as prophylactics and remedies for various diseases related to oxytocin oversecretion.

The ligand polypeptides of the present invention can therefore be useful as oxytocin secretion stimulator

drugs for ameliorating, preventing, or treating various diseases related to oxytocin secretion, such as uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced induced abortion, lacteal retension, induced labor, hypogalactia or hypergalactia or hypergalactia, infertility, dysmenorrhea, miscarriage, and posttraumatic stress syndrome, preferably uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced abortion, and lacteal retension, and particularly uterine inertia, atonic hemorrhage, placental expulsion, and subinvolution.

The ligand polypeptides of the present invention are also useful as oxytocin secretion inhibitor drugs for ameliorating, preventing, or treating various diseases related to oxytocin secretion, such as hypertonic labor, hypertonic uterine contractions, fetal distress, uterine rupture, cervical tears, premature birth, Prader-Willi syndrome, and dysmenorrhea, and preferably hypertonic labor, hypertonic uterine contractions, fetal distress, uterine rupture, cervical tears, premature birth, and Prader-Willi syndrome.

The ligand polypeptides of the present invention are also useful as test reagents for studying oxytocin secretion function, and as animal drugs such as lactating stimulators for livestock such as cows, goats, and pigs. Applications may also be anticipated for the production of useful substances that are produced in dairy animals and secreted in their milk.

Ligand polypeptides of the present invention that are used as such pharmaceutical or animal drugs may be employed in the usual manner. For example, they can be orally administered in the form of sugar-coated tablets,

capsules, elixirs, microcapsules, and the like, and can be parenterally administered in the form of injections such as sterile solutions with water or other pharmaceutically acceptable liquids, or suspensions. Such preparations can be manufactured, for example, by mixing the polypeptides or their salts in unit dose formulations required for generally recognized preparations, along with physiologically acceptable carriers, flavorings, excipients, vehicles, antiseptics, stabilizers, binders, and the like. The content of the active ingredient in such formulations will give a suitable dose within the indicated range.

Examples of additives miscible with tablets, capsules, and the like include binders such as gelatin, corn starch, tragacanth gum, and gum arabic, excipients such as crystalline cellulose, extenders such as corn starch, gelatin, and alginic acid, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose, and saccharin, and flavors such as peppermint, *Akamono* oil, or cherry. In the case of unit formulations in the form of capsule preparations, the aforementioned types of material can also include a liquid carrier such as a lipid or an oil. Sterile compositions for injections can be formulated by a common method such as dissolving or suspending a naturally produced vegetable oil or the like such as sesame oil or coconut oil and the active ingredient in a vehicle such as water for injection.

Examples of aqueous solutions for injection include physiological saline, isotonic solutions containing glucose or other adjuvants (such as D-sorbitol, D-mannitol, and sodium chloride). Suitable dissolving aids such as alcohols (such as ethanol), polyalcohols (such as propylene glycol and polyethylene glycol), and nonionic surfactants (such as Polysorbate 80™ and HCO-50) can also

be used. Examples of oleaginous solutions include sesame oil and soybean oil. Examples of dissolution aids include benzyl benzoate and benzyl alcohol. Buffers (such as phosphate buffers and sodium acetate buffers), soothing agents (such as benzalkonium and procaine hydrochloride), stabilizers (such as human serum albumin and polyethylene glycol), preservatives (such as benzyl alcohol and phenol), antioxidants, and the like can also be blended. Injections are usually aseptically packaged in suitable ampules.

The resulting preparation is safe and has low toxicity, and can thus be administered, for example, to humans and mammals (such as mice, rats, guinea pigs, rabbits, goats, pigs, cows, cats, dogs, monkeys, sacred baboons, and chimpanzees).

The dosage of the ligand polypeptides in the present invention varies depending on the subjects condition, etc. The orally administered dosage for patients suffering from uterine inertia during labor (per 60 kg body weight) is generally about 0.1 to 100 mg at a time, preferably about 1.0 to 50 mg, and even more preferably about 1.0 to 20 mg. The parenterally administered dosage at a time varies depending on the purpose of administration, the subject's condition, the method of administration, and so forth. Intravenous injections, for example, for patients suffering from uterine inertia (per 60 kg body weight) are generally about 0.01 to 30 mg at a time, preferably about 0.1 to 20 mg, and even more preferably about 0.1 to 10 mg. The dosage for other mammals can also be calculated in terms of 60 kg.

The G protein-coupled receptor proteins (henceforth, sometimes referred to as receptor proteins) or ligand

polypeptides used in the present invention can be prepared in accordance with WO 96/05302 or WO 97/24436.

Methods for acquisition and uses of oxytocin secretion regulators comprising compounds or their salts which alter the binding properties between the ligand polypeptides of the present invention for receptor proteins in the present invention and such receptor proteins are described below.

The compounds or their salts which alter the binding properties between the ligand polypeptides for receptor proteins in the present invention and such receptor proteins include compounds and their salts for stimulating the function (such as oxytocin secretion action) of the ligand polypeptides in the present invention, and compounds or their salts for inhibiting the function (such as oxytocin secretion action) of the ligand polypeptides in the present invention.

Since the ligand polypeptides of the present invention have action in regulating oxytocin secretion (such as action in promoting and inhibiting oxytocin secretion), compounds or their salts that promote the oxytocin secretion of the ligand polypeptides in the present invention can be used as oxytocin secretion promoter drugs for ameliorating, preventing, or treating diseases such as uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced abortion, lacteal retension, induced labor, hypogalactia or hypergalactia, infertility, dysmenorrhea, miscarriage, and posttraumatic stress syndrome, preferably uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced abortion, and lacteal retension, and particularly uterine

inertia, atonic hemorrhage, placental expulsion, and subinvolution.

Compounds or their salts that inhibit the oxytocin secretion action of the ligand polypeptides of the present invention are also useful as drugs for ameliorating, preventing, or treating diseases such as hypertonic labor, hypertonic uterine contractions, fetal distress, uterine rupture, cervical tears, premature birth, Prader-Willi syndrome, and dysmenorrhea, and preferably hypertonic labor, hypertonic uterine contractions, fetal distress, uterine rupture, cervical tears, premature birth, and Prader-Willi syndrome.

The ligand polypeptides of the present invention are therefore useful as reagents for screening compounds and their salts which promote or inhibit the function of the ligand polypeptides in the present invention.

Compounds and salts promoting or inhibiting the function of the ligand polypeptides in the present invention can be obtained by screening compounds which modify the bonding properties between G protein-coupled receptor proteins (such as phGR3 and UHR-1 (WO 96/05302 and WO 97/24436)) and the ligand polypeptides of the present invention.

Such screening methods are described below.

A G protein-coupled receptor protein (such as phGR3 and UHR-1 (WO 96/05302 and WO 97/24436)) expression system can be constructed, and a receptor-binding assay system feature the use of the above expression system can be employed for efficient screening of compounds (such as peptides, proteins, nonpeptidic compounds, synthetic compounds, and fermentation products) or their salts

which alter the binding properties between the ligand polypeptides of the present invention and G protein-coupled receptor proteins (such as phGR3 and UHR-1 (WO 96/05302 and WO 97/24436)).

Such compounds include: 1) compounds having cell stimulating activity mediated by G protein-coupled receptor proteins (such as activity in promoting or inhibiting the release of arachidonic acid, the release of acetylcholine, the release of intracellular Ca^{2+} , the production of intracellular cAMP, the production of intracellular cGMP, the production of inositolphosphoric acid, changes in cell membrane potential, the phosphorylation of intracellular protein, the c-fos activation, and pH reduction); 2) compounds with no such cell-stimulating activity (referred to as receptor protein antagonists); 3) compounds that potentiate the binding strength between the ligand polypeptides of the present invention and G protein-coupled receptor proteins; and 4) compounds that attenuate the binding strength between the ligand polypeptides of the present invention and G protein-coupled receptor proteins.

That is, the present invention provides a method for screening compounds or their salts that alter the binding properties between the ligand polypeptides or their salts in the present invention and receptor proteins or their salts, which is characterized by comparing (i) cases where contact is brought about between receptor proteins or their salts and the ligand polypeptides or their salts in the present invention and (ii) cases where contact is brought about between receptor proteins or their salts and the ligand polypeptides or their salts in the present invention and reagent compounds.

The screening method of the present invention is characterized in that the comparison between cases (i) and (ii) involves assaying the binding of the ligand to the receptor protein, the cell stimulating activity, or the like.

More specifically, the invention provides:

((1)) a method for screening compounds or salts that alter the binding properties between the ligand polypeptides or their salts in the present invention and such receptor proteins or the like, characterized by the assay and comparison of the extent to which labeled ligand polypeptides or salts of the present invention bind to receptor proteins in cases where labeled ligand polypeptides or their salts in the present invention are brought into contact with receptor proteins or the like, and cases where labeled ligand polypeptides or their salts and reagent compounds are brought into contact with the receptor proteins or the like in the present invention;

((2)) a method for screening compounds or salts that alter the binding properties between the ligand polypeptides or their salts of the present invention and such receptor proteins or the like, characterized by the assay and comparison of the extent to which labeled ligand polypeptides or salts of the present invention bind to cells or membrane fractions in cases where labeled ligand polypeptides or their salts of the present invention are brought into contact with cells containing receptor proteins or the like or membrane fractions of such cells, and cases where labeled ligand polypeptides or their salts and reagent compounds are brought into contact with cells containing receptor proteins or the like or membrane fractions of such cells; and

((3)) a method for screening compounds or salts that alter the binding properties between the ligand polypeptides of the present invention and such receptor proteins or the like, by the assay and comparison of the extent to which labeled ligand polypeptides of the present invention bind to receptor proteins in cases where labeled ligand polypeptides of the present invention are brought into contact with receptor proteins or the like expressed on cell membranes as a result of the culture of transformants containing DNA encoding such receptor proteins or the like, and cases where labeled ligand polypeptides of the present invention and reagent compounds are brought into contact with receptor proteins or the like expressed on cell membranes as a result of the culture of transformants containing DNA encoding such receptor proteins or the like.

The aforementioned screening methods are described in further detail below.

Any receptor protein including the above may be used as the receptor protein in the screening methods of the present invention, but cell membrane fractions of mammalian organs containing receptor proteins are preferred. However, because human organs in particular are extremely difficult to obtain, human receptor proteins that are mass produced through expression using recombinants are suitable for use in screening.

Receptor proteins are preferably manufactured by expression of DNA encoding receptors in the mammalian or insect cell. Complementary DNA may be used for DNA fragments encoding the target protein portion, but the options are not necessarily limited to this. For example, gene fragments and synthetic DNA may be used. In order

to introduce DNA fragments encoding receptor proteins into host animal cells for efficient expression, the DNA fragment should be inserted downstream of a promoter such as the polyhedrin promoter of a nuclear polyhedrosis virus (NPV) belonging to the baculovirus used with insect hosts, an SV40-derived promoter, a retrovirus promoter, a metallothionein promoter, a human heat shock promoter, a cytomegalovirus promoter, an SR α promoter, or the like. The amount and quality of the expressed receptors can be determined by a publicly known method. This can be done, for example, in accordance with the method in P. Manbi et al., *J. Biol. Chem.*, Vol. 267, pp. 19555-19559 (1992).

Examples of receptor proteins for the aforementioned screening methods include receptor proteins purified by publicly known methods, cells containing such receptor proteins, and membrane fractions of cells containing such receptor proteins.

When cells containing the receptor proteins of the present invention are used in the aforementioned screening methods, the cells may be fixed with glutaraldehyde, formalin, or the like. The cells can be fixed by a publicly known method.

Cells containing receptor proteins refer to host cells expressing the receptor proteins. Preferred examples of host cells include *E. coli*, *Bacillus subtilis*, yeasts, insect cells, and animal cells.

Cell membrane fractions refer to fractions containing an abundance of cell membranes, obtained by publicly known methods following the disruption of cells. Methods of cell disruption include the method for squeezing cells in a Potter-Elvehjem homogenizer, disruption with a waring blender or Polytron (by

Kinematica), disruption by ultrasonication, and the method in which cells are ejected through a narrow nozzle while pressed by a French press. Fractionation by centrifugal force such as centrifugation for fractionation, density gradient centrifugation, and the like is primarily used for fractionation of cell membranes. For example, the disrupted cell suspension is briefly centrifuged (usually about 1 to 10 minutes) at low speed (500 to 3000 rpm), the supernatant is then further centrifuged, usually for 30 minutes to 2 hours at high speed (15,000 to 30,000 rpm), and the resulting precipitate is obtained in the form of membrane fractions. The membrane fractions contain many membrane components such as membrane proteins or cellular phospholipids as well as the expressed receptor proteins.

The amount of receptor protein in the membrane fractions or cells containing receptor proteins is preferably 10^3 to 10^8 molecules, and ideally 10^5 to 10^7 molecules, per cell. The greater the amount expressed, the higher the ligand binding activity (specific activity) per membrane fraction, the higher the sensitivity of the screening system that can be constructed, and the greater the amount of sample that can be assayed in the same lot.

Suitable receptor protein fractions and labeled ligand polypeptides or their salts of the present invention are needed, for example, in order to screen compounds that alter the binding properties between the ligand polypeptides or their salts of the present invention and receptor proteins.

Preferred examples of receptor protein fractions include natural receptor protein fractions, as well as recombinant receptor protein fractions having the same

activity as natural types. As used here, "the same activity" means the same ligand binding activity, signal transducing action, and the like.

Labeled ligands, labeled ligand analog compounds, and the like may be used as the labeled ligands.

Examples include ligands labeled with [³H], [¹²⁵I], [¹⁴C], [³⁵S], and the like.

Specifically, in order to screen for compounds that alter the binding properties between the ligand polypeptides of the present invention and receptor proteins, cell membrane fractions or cells containing the receptor proteins are first suspended in a buffer suitable for screening, so as to prepare a receptor protein preparation. The buffer may be any that does not inhibit binding between the ligand and receptor protein, such as phosphate buffer and Tris-HCl buffer with a pH of between 4 and 10 (and preferably a pH of 6 to 8). A surfactant such as CHAPS, Tween-80™ (Kao-Atlas), digitonin, or deoxycholate can be added to the buffer in order to minimize non-specific binding. A protease inhibitor such as PMSF, leupeptin, E-64 (by Peptide Kenkyusho), or pepstatin can be added to inhibit the degradation of the ligand or receptor by protease. A given amount (5000 cpm to 500,000 cpm) of labeled ligand is added to 0.01 mL to 10 mL of the receptor solution, while 10⁻⁴ M to 10⁻¹⁰ M test compound is simultaneously coexisted. A reaction tube containing an excess of unlabeled ligand is also prepared to ascertain the extent of non-specific binding (NSB). The reaction is carried out for about 20 minutes to 24 hours, and preferably about 30 minutes to 3 hours, at about 0 to 50°C, and preferably about 4 to 37°C. After the reaction, the solution is filtered with glass fiber filter paper or the like and washed with a suitable amount of the same buffer,

and the radioactivity remaining on the glass fiber filter paper is measured with a liquid scintillation counter or γ -counter. Candidates with potential competitive inhibition can be selected, for example, from test compounds with no more than 50% specific binding (B-NSB), where 100% is the count (B_0 -NSB) obtained by subtracting the non-specific binding (NSB) from the count prevailing in the absence of any competing substance (B_0).

Publicly known methods or commercially available assay kits can be used to assay receptor protein-mediated cell-stimulating activity (such as activity in promoting or inhibiting the release of arachidonic acid, the release of acetylcholine, the release of intracellular Ca, the production of intracellular cAMP, the production of intracellular cGMP, the production of inositolphosphoric acid, changes in cell membrane potential, the phosphorylation of intracellular protein, the c-fos activation, and pH reduction) in order to implement the method for screening compounds that alter the binding properties between the ligand polypeptides of the present invention and receptor proteins.

Specifically, cells containing receptor proteins are first cultured in multi-well plates or the like. For screening, the medium or buffer is replaced by fresh medium or a suitable buffer that shows no toxicity to the cells, reagent compounds or the like are added for incubation lasting for a certain period of time, and the cells are then extracted or the supernatant is recovered to quantify the product by a variety of methods. When the production of the substance having the cell-stimulating activity (such as arachidonic acid) is difficult to detect due to degrading enzymes contained in the cells, the assay may be undertaken with the addition of inhibitors for such degrading enzymes. Activity such

as the inhibition of cAMP production can be determined in terms of the inhibition of production with regard to cells in which basal production has been increased such as with forskolin.

Cells expressing suitable receptor proteins are necessary for the assay and screening of cell-stimulating activity. Preferred examples of cells expressing receptor proteins include cell lines having natural types of the receptor proteins in the present invention, and cell lines expressing the aforementioned recombinant receptor proteins.

Examples of test compounds include peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, vegetable extracts, and animal tissue extracts. Such compounds may be novel compounds or publicly known compounds.

A screening kit for compounds or their salts that alter the binding properties between the ligand polypeptides of the present invention and receptor proteins will include receptor proteins, cells containing receptor proteins, or membrane fractions of cells containing receptor proteins.

Examples of screening kits in the present invention are given below.

1. Screening Reagents

((1)) Assay buffer and washing buffer

Hanks' balanced salt solution (Gibco) supplemented with 0.05% bovine serum albumin (Sigma)

This may be sterilized by filtration with a filter having a pore diameter of 0.45 μm and stored at 4°C, or prepared at the use.

((2)) G protein-coupled receptor preparations

CHO cells expressing receptor proteins are subcultured in a concentration of 5×10^5 cells/well in 12-well plates, and are cultured for 2 days at 37°C in 5% CO₂ and 95% air.

((3)) Labeled ligands

Commercially available ligand polypeptides of the present invention labeled with [³H], [¹²⁵I], [¹⁴C], [³⁵S], or the like

Aqueous solution is stored at 4°C or -20°C, and diluted to 1 μM with assay buffer at use.

((4)) Ligand reference solution

The ligands of the present invention are dissolved to a concentration of 1 mM in PBS containing 0.1% bovine serum albumin, and stored at -20°C.

2. Assay method

((1)) CHO cells expressing receptor proteins cultured in 12-well tissue culturing plates are washed twice with 1 mL of assay buffer, and 490 μL of assay buffer is then added to each well.

((2)) 5 μ L of 10^{-3} to 10^{-10} M reagent compound solution is added, 5 μ L of labeled ligand is then added, and a reaction is brought about for 1 hour at room temperature. 5 μ L of 10^{-3} M ligand is added instead of the test compound in order to ascertain the extent of non-specific binding.

((3)) The reaction solution is removed, and the cells are washed three times with 1 mL of washing buffer. The labeled ligand binding to the cells is dissolved in 0.2 N NaOH-1% SDS and mixed with 4 mL liquid Scintillator A (Wako Pure Chemicals).

((4)) The radioactivity is measured using a liquid scintillation counter (Beckmann), and the percent maximum binding (PMB) is determined using the following equation.

$$\text{PMB} = [(B - \text{NSB}) / (B_0 - \text{NSB})] \times 100$$

PMB: percent maximum binding

B: value when the sample was added

NSB: non-specific binding

B_0 : maximum binding

Compounds or their salts modifying the binding properties between receptor proteins and the ligand polypeptides of the present invention for receptors in the present invention may be employed in the usual manner as oxytocin secretion regulators. For example, they can be orally administered in the form of sugar-coated tablets, capsules, elixirs, microcapsules, and the like, and can be used in the form of nasal drops or parenterally administered in the form of injections such as sterile solutions with water or other pharmaceutically acceptable liquids, or suspensions. Such preparations

can be manufactured, for example, by mixing the compounds or their salts in unit dose formulations required for generally recognized preparations, along with physiologically acceptable carriers, flavorings, excipients, vehicles, antiseptics, stabilizers, binders, and the like. The content of the active ingredient in such formulations will give a suitable dose within the indicated range.

Examples of additives miscible with tablets, capsules, and the like include binders such as gelatin, corn starch, tragacanth gum, and gum arabic, excipients such as crystalline cellulose, extenders such as corn starch, gelatin, and alginic acid, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose, and saccharin, and flavors such as peppermint, Akamono oil, or cherry. In the case of unit formulations in the form of capsule preparations, the aforementioned types of material can also include a liquid carrier such as a lipid or an oil. Sterile compositions for injections can be formulated by a common method such as dissolving or suspending a naturally produced vegetable oil or the like such as sesame oil or coconut oil and the active ingredient in a vehicle such as water for injection.

Examples of aqueous solutions for injection include physiological saline, isotonic solutions containing glucose or other adjuvants (such as D-sorbitol, D-mannitol, and sodium chloride). Suitable dissolving aids such as alcohols (such as ethanol), polyalcohols (such as propylene glycol and polyethylene glycol), and nonionic surfactants (such as Polysorbate 80™ and HCO-50) can also be used. Examples of oleaginous solutions include sesame oil and soybean oil. Examples of dissolution aids include benzyl benzoate and benzyl alcohol. Buffers (such as phosphate buffers and sodium acetate buffers),

soothing agents (such as benzalkonium and procaine hydrochloride), stabilizers (such as human serum albumin and polyethylene glycol), preservatives (such as benzyl alcohol and phenol), antioxidants, and the like can also be blended. Injections are usually aseptically packaged in suitable ampules.

The resulting preparation is safe and low toxic, and can thus be administered, for example, to humans and mammals (such as mice, rats, guinea pigs, rabbits, goats, pigs, cows, cats, dogs, monkeys, and chimpanzees).

The dosage of the oxytocin secretion regulators containing the compounds or their salts in the present invention varies depending on the subjects condition, etc. The orally administered dosage for patients suffering from uterine inertia during labor (per 60 kg body weight) is generally about 0.1 to 100 mg at a time, preferably about 1.0 to 50 mg, and even more preferably about 1.0 to 20 mg. The parenterally administered dosage at a time varies depending on the purpose of administration, the subject's condition, the method of administration, and so forth. Intravenous injections, for example, for patients suffering from uterine inertia (per 60 kg body weight) are generally about 0.01 to 30 mg at a time, preferably about 0.1 to 20 mg, and even more preferably about 0.1 to 10 mg. The dosage for other mammals can also be calculated in terms of 60 kg.

The SEQ ID Nos: in the Sequence Listing in the Specification indicate the following sequences.

[SEQ ID NO: 1]

Full length amino acid sequence of bovine hypothalamus derived ligand polypeptide contained in pBOV3.

[SEQ ID NO: 2]

Entire base sequence of the cDNA for bovine hypothalamus derived ligand polypeptide.

[SEQ ID NO: 3]

Amino acid sequence of bovine hypothalamus derived ligand polypeptide, corresponding to the amino acid sequence from 23 to 53 in SEQ ID NO: 1.

[SEQ ID NO: 4]

Amino acid sequence of bovine hypothalamus derived ligand polypeptide, corresponding to the amino acid sequence from 23 to 54 in SEQ ID NO: 1.

[SEQ ID NO: 5]

Amino acid sequence of bovine hypothalamus derived ligand polypeptide, corresponding to the amino acid sequence from 23 to 55 in SEQ ID NO: 1.

[SEQ ID NO: 6]

Amino acid sequence of bovine hypothalamus derived ligand polypeptide, corresponding to the amino acid sequence from 34 to 53 in SEQ ID NO: 1.

[SEQ ID NO: 7]

Amino acid sequence of bovine hypothalamus derived ligand polypeptide, corresponding to the amino acid sequence from 34 to 54 in SEQ ID NO: 1.

[SEQ ID NO: 8]

Amino acid sequence of bovine hypothalamus derived ligand polypeptide, corresponding to the amino acid sequence from 34 to 55 in SEQ ID NO: 1.

[SEQ ID NO: 9]

Base sequence of DNA encoding bovine hypothalamus derived ligand polypeptide (SEQ ID NO: 3)

[SEQ ID NO: 10]

Base sequence of DNA encoding bovine hypothalamus derived ligand polypeptide (SEQ ID NO: 4)

[SEQ ID NO: 11]

Base sequence of DNA encoding bovine hypothalamus derived ligand polypeptide (SEQ ID NO: 5)

[SEQ ID NO: 12]

Base sequence of DNA encoding bovine hypothalamus derived ligand polypeptide (SEQ ID NO: 6)

[SEQ ID NO: 13]

Base sequence of DNA encoding bovine hypothalamus derived ligand polypeptide (SEQ ID NO: 7)

[SEQ ID NO: 14]

Base sequence of DNA encoding bovine hypothalamus derived ligand polypeptide (SEQ ID NO: 8)

[SEQ ID NO: 15]

Full length amino acid sequence of bovine genome derived ligand polypeptide.

[SEQ ID NO: 16]

Full length amino acid sequence of rat ligand polypeptide.

[SEQ ID NO: 17]

Total base sequence of cDNA for rat ligand polypeptide.

[SEQ ID NO: 18]

Amino acid sequence of rat ligand polypeptide, corresponding to the amino acid sequence from 22 to 52 in SEQ ID NO: 16.

[SEQ ID NO: 19]

Amino acid sequence of rat ligand polypeptide, corresponding to the amino acid sequence from 22 to 53 in SEQ ID NO: 16.

[SEQ ID NO: 20]

Amino acid sequence of rat ligand polypeptide, corresponding to the amino acid sequence from 22 to 54 in SEQ ID NO: 16.

[SEQ ID NO: 21]

Amino acid sequence of rat ligand polypeptide,
corresponding to the amino acid sequence from 33 to 52 in
SEQ ID NO: 16.

[SEQ ID NO: 22]

Amino acid sequence of rat ligand polypeptide,
corresponding to the amino acid sequence from 33 to 53 in
SEQ ID NO: 16.

[SEQ ID NO: 23]

Amino acid sequence of rat ligand polypeptide,
corresponding to the amino acid sequence from 33 to 54 in
SEQ ID NO: 16.

[SEQ ID NO: 24]

Base sequence of DNA encoding rat ligand polypeptide
(SEQ ID NO: 18)

[SEQ ID NO: 25]

Base sequence of DNA encoding rat ligand polypeptide
(SEQ ID NO: 19)

[SEQ ID NO: 26]

Base sequence of DNA encoding rat ligand polypeptide
(SEQ ID NO: 20)

[SEQ ID NO: 27]

Base sequence of DNA encoding rat ligand polypeptide
(SEQ ID NO: 21)

[SEQ ID NO: 28]

Base sequence of DNA encoding rat ligand polypeptide
(SEQ ID NO: 22)

[SEQ ID NO: 29]

Base sequence of DNA encoding rat ligand polypeptide
(SEQ ID NO: 23)

[SEQ ID NO: 30]

Full length amino acid sequence of human ligand
polypeptide.

[SEQ ID NO: 31]

Total base sequence of cDNA for human ligand
polypeptide.

[SEQ ID NO: 32]

Amino acid sequence of human ligand polypeptide,
corresponding to the amino acid sequence from 23 to 53 in
SEQ ID NO: 30.

[SEQ ID NO: 33]

Amino acid sequence of human ligand polypeptide,
corresponding to the amino acid sequence from 23 to 54 in
SEQ ID NO: 30.

[SEQ ID NO: 34]

Amino acid sequence of human ligand polypeptide,
corresponding to the amino acid sequence from 23 to 55 in
SEQ ID NO: 30.

[SEQ ID NO: 35]

Amino acid sequence of human ligand polypeptide,
corresponding to the amino acid sequence from 34 to 53 in
SEQ ID NO: 30.

[SEQ ID NO: 36]

Amino acid sequence of human ligand polypeptide,
corresponding to the amino acid sequence from 34 to 54 in
SEQ ID NO: 30.

[SEQ ID NO: 37]

Amino acid sequence of human ligand polypeptide,
corresponding to the amino acid sequence from 34 to 55 in
SEQ ID NO: 30.

[SEQ ID NO: 38]

Base sequence of DNA encoding human ligand
polypeptide (SEQ ID NO: 32).

[SEQ ID NO: 39]

Base sequence of DNA encoding human ligand
polypeptide (SEQ ID NO: 33).

[SEQ ID NO: 40]

Base sequence of DNA encoding human ligand
polypeptide (SEQ ID NO: 34).

[SEQ ID NO: 41]

Base sequence of DNA encoding human ligand polypeptide (SEQ ID NO: 35).

[SEQ ID NO: 42]

Base sequence of DNA encoding human ligand polypeptide (SEQ ID NO: 36).

[SEQ ID NO: 43]

Base sequence of DNA encoding human ligand polypeptide (SEQ ID NO: 37).

[SEQ ID NO: 44]

Amino acid sequence of ligand polypeptide in present invention, wherein the Xaa at 10 is Ala or Thr, the Xaa at 11 is Gly or Ser, and the Xaa at 21 is H, Gly, or GlyArg.

[SEQ ID NO: 45]

Amino acid sequence of ligand polypeptide in present invention, wherein the Xaa at 10 is Thr or Ala, and the Xaa at 11 is Gly or Ser.

Examples and reference examples are given below to illustrate the present invention in further detail, but the scope of the present invention is not limited by these examples.

Example 1

Determination of the distribution of PrRP (19P2-L31)
in rat organs

Male Wistar rats were decapitated, the pancreas organs were delivered to weigh the tissue, and the organs were immediately frozen using liquid nitrogen. PrRP (19P2-L31) was extracted from the organs by adding 10-fold distilled water to each of the organs, which were heat treated for 10 minutes in boiling water to inactivate the protease and then cooled in ice. Glacial acetic acid (final concentration of 1 N), pepstatin (final concentration of 1 µg/mL), and phosphoramidone (final concentration of 100 µg/mL) were added, and then the mixture was homogenized for 1 minute in a Polytron homogenizer (Kinematica), and then centrifuged for 30 minutes at 17,000 × g. The resulting organ extract was concentrated with a 265 mg of Sep-Pak Plus C18 cartridge (Waters), and PrRP (19P2-L31) described in *Nature*, Vol. 393, pp. 272-276 (1998) and WO 97/24436 was quantified using the previously reported sandwich EIA system (Japanese Patent Application H10-140293 and WO 99/60112). 4 mL of 86% ethanol containing 4% acetic acid, 4 mL of methanol, 4 mL of distilled water, and 4 mL of 4% acetic acid were poured, in that sequence, to the activated Sep-Pak Plus C18 cartridge, to which the extract was added, and the cartridge was then washed with 10 mL of distilled water and then eluted with 4 mL of 86% ethanol containing 4% acetic acid and 4 mL of methanol to concentrate the extract in a nitrogen stream at 37°C. The concentrated fractions were reconstructed in 0.25 mL of buffer C (0.02 M phosphate buffer (pH 7) containing 10% Bloc Ace, 0.2% BSA, 0.4 M NaCl, and 0.05% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]propanesulfonic acid)) and quantified by sandwich EIA. The results are shown in Figure 1. PrRP (19P2-L31) immune activity of 0.53 ± 0.06

pmol/g tissue (mean \pm SEM, n = 5) was detected in rat posterior pituitary gland.

Example 2

Effect of third intraventricular administration of PrRP (19P2-L31) on amount of oxytocin secreted in plasma

Mature male Wistar rats (weighing 350 to 380 g at the time of surgery) were anesthetized by intraperitoneal administration of 50 mg/kg pentobarbital, and were fixed in a rat brain stereotactic instrument. The brace bar was lowered 3.3 mm from the intra-oral line. The cranial bone was exposed, and a dental drill was used to perforate the bone in order to implant a guide cannula AG-12 (inside diameter 0.4 mm, outside diameter 0.5 mm, Eicom) into the third ventricle. Anchor screws were embedded in four locations around the cannula. The stainless steel guide cannula AG-12 was inserted to a position at the top of the third ventricle. Position coordinates were AP: +7.1 mm, L: 0.0 mm, and H: +2.0 mm, in accordance with the atlas of Paxinos and Watson (1986). The guide cannula was secured to the cranial bone using instant adhesive, dental cement, and the anchor screws. A stainless steel dummy cannula AD-12 (outside diameter 0.35 mm, Eicom) was inserted into the guide cannula and secured with a cap nut (Eicom). Following surgery, the rats were bred in individual cages.

Animal were given about 1 week to recover after implantation of the guide cannulas, and blood was drawn as the animals were allowed to move freely. Rats which had undergone the aforementioned surgery were anesthetized by intraperitoneal administration of 50 mg/kg pentobarbital. The animals were positioned on their backs on necropsy pads, and the jugular vein on the

left side was exposed. Polyethylene tubes SP 35 (inside diameter 0.5 mm, outside diameter 0.9 mm, Natsume Seisakusho) were cut to a length of about 30 cm, were filled with physiological saline containing 200 units/mL heparin, and were inserted about 4.5 cm into the jugular veins and secured. The other end of the tubes were passed under the dorsal skin and exposed from the cervical region (dorsal side).

One night after surgery, 400 μ L of blood was drawn using a 1 mL tuberculin syringe and 25 gauge needle (both by Terumo) 30 minutes before administration of PrRP (19P2-L31). 20 μ L of physiological saline containing 200 units/mL heparin was introduced into the syringe to prevent blood coagulation. The cap nut and dummy cannula attached to the cranial bone of the rats were removed, and in their place a stainless steel microinjection cannula (inside diameter 0.17 mm, outside diameter 0.35 mm, Eicom) connected to a Teflon tube (50 cm long, inside diameter 0.1 mm, outside diameter 0.35 mm, Eicom) was inserted. The length of the microinjection cannula was adjusted so that the tip was exposed 1 mm from the guide cannula. One end of the Teflon tube was connected to a microsyringe pump, and either phosphate-buffered physiological saline containing 0.5% BSA in which PrRP (19P2-L31) had been dissolved or phosphate-buffered physiological saline containing 0.5% bovine serum albumin (BSA) was injected at a rate of 5 μ L/min into the third ventricle. 15 minutes after the injection, the microinjection cannula was removed, and the dummy cannula was again secured with the cap nut. 400 μ L samples of blood were drawn from the jugular vein immediately before and 5, 15, 30, 45, and 60 minutes after the intraventricular administration. The drawn blood was centrifuged (5,000 rpm, 10 min) using a high speed cooled

microcentrifuge (MR-150, Tomy Seiko), and the supernatant (plasma) was recovered. The oxytocin in the plasma was assayed by radioimmunoassay (Peninsula). As shown in Figure 2, the oxytocin concentration in blood was about 2 times higher than the control group 5 minutes after the administration of 10 nmol PrRP (19P2-L31) to the third ventricle.

Preparation Example 1

50 mg of the compound obtained in Example 21 was dissolved in 50 mL of Japan Pharmacopoeia distilled water, and Japan Pharmacopoeia distilled water was added to bring the total to 100 mL. The solution was aseptically filtered, and 1 mL portions of the solution were then used to fill injection vials under aseptic conditions, lyophilized, and sealed.

Preparation Example 2

100 mg of the compound obtained in Example 21 was dissolved in 50 mL of Japan Pharmacopoeia distilled water, and Japan Pharmacopoeia distilled water was added to bring the total to 100 mL. The solution was aseptically filtered, and 1 mL portions of the solution were then used to fill injection vials under aseptic conditions, lyophilized, and sealed.

INDUSTRIAL APPLICABILITY

The ligand polypeptides of the present invention have action in regulating oxytocin secretion (action in promoting and inhibiting oxytocin secretion). That is, the ligand polypeptides in the present invention have action in promoting oxytocin secretion, and thus can be used as prophylactics and remedies for various diseases

related to insufficient oxytocin secretion. The ligand polypeptides in the present invention also have strong affinity for receptor proteins, and thus have action in inhibiting oxytocin secretion as a result of desensitization with regard to oxytocin secretion when the dosage is increased. The ligand polypeptides can therefore also be used as prophylactics and remedies for various diseases related to oxytocin oversecretion.

Therefore, the ligand polypeptides of the present invention can be useful as oxytocin secretion stimulating drugs for ameliorating, preventing, or treating various diseases related to oxytocin secretion, such as uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced abortion, lacteal retension, induced labor, hypogalactia or hypergalactia, infertility, dysmenorrhea, miscarriage, and posttraumatic stress syndrome, preferably uterine inertia, atonic hemorrhage, placental expulsion, subinvolution, cesarean section, induced abortion, and lacteal retension, and particularly uterine inertia, atonic hemorrhage, placental expulsion, and subinvolution.

The ligand polypeptides of the present invention are also useful as oxytocin secretion depressor, and drugs for ameliorating, preventing, or treating various diseases related to oxytocin secretion, such as hyperdynamia uteri, hypertonic uterine contractions, fetal distress, uterine rupture, cervical tears, premature birth, Prader-Willi syndrome, and dysmenorrhea, and preferably hyperdynamia uteri, hypertonic uterine contractions, fetal distress, uterine rupture, cervical tears, premature birth, and Prader-Willi syndrome.

The ligand polypeptides of the present invention are also useful as test reagents for studying oxytocin

secretion function, and as animal drugs such as lactating stimulators for livestock such as cows, goats, and pigs. Applications may also be anticipated for the production of useful substances that are produced in dairy animals and secreted in their milk.

CLAIMS

1. An oxytocin secretion regulator, comprising a ligand peptide, or salt thereof, for a G protein-coupled receptor protein.

2. An oxytocin secretion regulator according to Claim 1, wherein the ligand peptide, or salt thereof, for a G protein-coupled receptor protein is a polypeptide, or an amide or an ester or a salt thereof, containing an amino acid sequence that is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 44.

3. An oxytocin secretion regulator according to Claim 2, wherein the amino acid sequence represented by SEQ ID NO: 44 is SEQ ID NO: 3, 18, or 32.

4. An oxytocin secretion regulator according to Claim 1, wherein the ligand peptide, or salt thereof, for a G protein-coupled receptor protein is a polypeptide, or an amide or an ester or a salt thereof, containing an amino acid sequence that is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 45.

5. An oxytocin secretion regulator according to Claim 4, wherein the amino acid sequence represented by SEQ ID NO: 45 is SEQ ID NO: 6, 21, or 35.

6. An oxytocin secretion regulator according to Claim 1, comprising an oxytocin secretion promoter.

7. An oxytocin secretion stimulator according to Claim 6, comprising a drug for ameliorating, preventing, or treating uterine inertia, atonic hemorrhage, placental

expulsion, subinvolution, cesarean section, induced abortion, or lacteal retension.

8. The use of a ligand peptide, or salt thereof, for a G protein-coupled receptor protein in order to regulate oxytocin secretion.

9. The use of a ligand peptide, or salt thereof, for a G protein-coupled receptor protein in order to manufacture an oxytocin secretion regulator.

10. A method for regulating oxytocin secretion, characterized by administering a ligand peptide, or salt thereof, for a G protein-coupled receptor protein to mammals with a disease related to insufficient oxytocin secretion.

Abstract

The present invention relates to use of peptide to which G-protein coupled receptor protein recognizes as a ligand. Since the ligand polypeptide of the present invention has a stimulating action on oxytocin secretion, it is useful as a drug for ameliorating, preserving or treating various diseases related to oxytocin secretion such as uterine inertia, atonic hemorrhage, placental expulsion, subinvolution and the like.

Fig. 1





Fig. 2

Effects of PrRP administration to third ventricle of male Wistar rat on oxytocin concentration in blood plasma



DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
130 Water Street
Boston, Massachusetts 02109

55999 (46342)

Docket No. 55999 (46342)

Page 1 of 4

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

which is described and claimed in:

the specification attached hereto.
 the specification in U.S. Application Serial Number _____, filed on _____

the specification in PCT international application Number PCT/JP99/07199, filed on December 22, 1999 and was amended on _____.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:

Application No.	Filing Date	Country	Priority Claimed Under 35 U.S.C. §119?
369585/1998	December 25, 1998	JP	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
			<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
			<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
			<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO

100 201	FULL NAME OF INVENTOR	LAST NAME <u>Matsumoto</u>	FIRST NAME <u>Hirokazu</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Ibaraki</u> <u>JPX</u>	STATE OR FOREIGN COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Takedakasuga Haitsu 1204, 7-9, Kasuga 1-chome, Tsukuba-shi, Ibaraki 305-0821 Japan</u>		

200 202	FULL NAME OF INVENTOR	LAST NAME <u>Kitada</u>	FIRST NAME <u>Chieko</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Osaka</u> <u>JPX</u>	STATE OR FOREIGN COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2-8, Minamikoyacho 1-cho, Sakai-shi, Osaka 590-0073 Japan</u>		

300 203	FULL NAME OF INVENTOR	LAST NAME <u>Hinuma</u>	FIRST NAME <u>Shuji</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Ibaraki</u> <u>JPX</u>	STATE OR FOREIGN COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Takedakasuga Haitsu 1402, 7-9, Kasuga 1-chome, Tsukuba-shi, Ibaraki 305-0821 Japan</u>		

204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		

205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S.-Benefit Under 35 U.S.C. §120				
U.S. Applications		Status (Check One)		
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned
PCT Applications Designating the U.S.				
Application No.	Filing Date	U.S. Serial No. Assigned		

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. §119(e))**

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Sewall P. Bronstein (Reg. No. <u>16,919</u>)	Peter F. Corless (Reg. No. <u>33,860</u>)	Richard E. Gamache (Reg. No. <u>39,196</u>)
David G. Conlin (Reg. No. <u>27,026</u>)	Cara Z. Lowen (Reg. No. <u>38,227</u>)	David A. Tucker (Reg. No. <u>27,840</u>)
George W. Neuner (Reg. No. <u>26,964</u>)	William J. Daley, Jr. (Reg. No. <u>35,487</u>)	Lisa Hazzard Swiszcz (Reg. No. <u>44,368</u>)
Linda M. Buckley (Reg. No. <u>31,003</u>)	Robert L. Buchanan (Reg. No. <u>40,927</u>)	
Peter J. Manus (Reg. No. <u>26,766</u>)	Christine C. O'Day (Reg. No. <u>38,256</u>)	

SEND CORRESPONDENCE TO: David G. Conlin <u>Dike, Bronstein, Roberts & Cushman, LLP</u> 130 Water Street Boston, Massachusetts 02109	DIRECT TELEPHONE CALLS TO: (617) 523-3400
--	---

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 Hirokazu Matsumoto	Date: <i>Hirokazu Matsumoto</i> <i>May 10, 2001</i>
Signature of Inventor 202 Chieko Kitada	Date: <i>Chieko Kitada</i> <i>May 10, 2001</i>
Signature of Inventor 203 Shuji Hinuma	Date: <i>Shuji Hinuma</i> <i>May 10, 2001</i>
Signature of Inventor 204	Date:
Signature of Inventor 205	Date:

09/868885

SEQUENCE LISTING

<110> Takeda Chemical Industries, Ltd.

<120> Use of Peptide

<130> 2584WOOP

<150> JP 10-369585

<151> 1998-12-25

<160> 45

<210> 1

<211> 98

<212> PRT

<213> Bovine

<400> 1

Met Lys Ala Val Gly Ala Trp Leu Leu Cys Leu Leu Leu Gly Leu

1 5 10 15

Ala Leu Gln Gly Ala Ala Ser Arg Ala His Gln His Ser Met Glu Ile

20 25 30

Arg Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg

35 40 45

Pro Val Gly Arg Phe Gly Arg Arg Ala Ala Pro Gly Asp Gly Pro

50 55 60

Arg Pro Gly Pro Arg Arg Val Pro Ala Cys Phe Arg Leu Glu Gly Gly

65 70 75 80

Ala Glu Pro Ser Arg Ala Leu Pro Gly Arg Leu Thr Ala Gln Leu Val

85 90 95

2/17

Gln Glu

<210> 2

<211> 294

<212> DNA

<213> Bovine

<400> 2

ATGAAGGCAGG TGGGGGCCTG GCTCCTCTGC CTGCTGCTGC TGGGCCTGGC CCTGCAGGGG 60

GCTGCCAGCA GAGCCCACCA GCACTCCATG GAGATCCGCA CCCCCGACAT CAACCCCTGCC 120

TGGTACGCRG GCCGTGGGAT CCGGCCCCGTG GGCCGCTTCG GCCGGCGAAG AGCTGCCCYG 180

GGGGACGGAC CCAGGCCTGG CCCCCGGCGT GTGCCGGCCT GCTTCCGCCT GGAAGGGCGY 240

GCTGAGCCCT CCCGAGCCCT CCCGGGGCGG CTGACGGCCC AGCTGGTCCA GGAA 294

<210> 3

<211> 31

<212> PRT

<213> Bovine

<400> 3

Ser Arg Ala His Gln His Ser Met Glu Ile Arg Thr Pro Asp Ile Asn

1

5

10

15

Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro Val Gly Arg Phe

20

25

30

<210> 4

<211> 32

<212> PRT

<213> Bovine

<400> 4

3/17

Ser Arg Ala His Gln His Ser Met Glu Ile Arg Thr Pro Asp Ile Asn

1

5

10

15

Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro Val Gly Arg Phe Gly

20

25

30

<210> 5

<211> 33

<212> PRT

<213> Bovine

<400> 5

Ser Arg Ala His Gln His Ser Met Glu Ile Arg Thr Pro Asp Ile Asn

1

5

10

15

Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro Val Gly Arg Phe Gly

20

25

30

Arg

33

<210> 6

<211> 20

<212> PRT

<213> Bovine

<400> 6

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe

20

<210> 7

4/17

<211> 21

<212> PRT

<213> Bovine

<400> 7

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe Gly

20

<210> 8

<211> 22

<212> PRT

<213> Bovine

<400> 8

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe Gly Arg

20

<210> 9

<211> 93

<212> DNA

<213> Bovine

<400> 9

AGCAGAGCCC ACCAGCACTC CATGGAGATC CGCACCCCCG ACATCAACCC TGCCTGGTAC 60

GCRGGCCGTG GGATCCGGCC CGTGGGCCGC TTC 93

<210> 10

<211> 96

<212> DNA

<213> Bovine

<400> 10

AGCAGAGCCC ACCAGCACTC CATGGAGATC CGCACCCCCG ACATCAACCC TGCCTGGTAC 60

GCRGGCCGTG GGATCCGGCC CGTGGGCCGC TTCGGC 96

<210> 11

<211> 99

<212> DNA

<213> Bovine

<400> 11

AGCAGAGCCC ACCAGCACTC CATGGAGATC CGCACCCCCG ACATCAACCC TGCCTGGTAC 60

GCRGGCCGTG GGATCCGGCC CGTGGGCCGC TTCGGCCGG 99

<210> 12

<211> 60

<212> DNA

<213> Bovine

<400> 12

ACCCCCGACA TCAACCCCTGC CTGGTACGCR GGCGTGGGA TCCGGCCCGT GGGCCGCTTC 60

<210> 13

<211> 63

<212> DNA

<213> Bovine

<400> 13

ACCCCCGACA TCAACCCCTGC CTGGTACGCR GGCGTGGGA TCCGGCCCGT GGGCCGCTTC 60

6/17

GGC 63

<210> 14

<211> 66

<212> DNA

<213> Bovine

<400> 14

ACCCCGACA TCAACCTGC CTGGTACGCR GGCGTGGGA TCCGGCCCGT GGGCCGCTTC 60

GGCCGG 66

<210> 15

<211> 98

<212> PRT

<213> Bovine

<400> 15

Met Lys Ala Val Gly Ala Trp Leu Leu Cys Leu Leu Leu Gly Leu

1

5

10

15

Ala Leu Gln Gly Ala Ala Ser Arg Ala His Gln His Ser Met Glu Ile

20

25

30

Arg Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg

35

40

45

Pro Val Gly Arg Phe Gly Arg Arg Ala Ala Leu Gly Asp Gly Pro

50

55

60

Arg Pro Gly Pro Arg Arg Val Pro Ala Cys Phe Arg Leu Glu Gly Gly

65

70

75

80

Ala Glu Pro Ser Arg Ala Leu Pro Gly Arg Leu Thr Ala Gln Leu Val

85

90

95

<212> PRT

<213> Rat

<400> 23

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Thr Gly Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe Gly Arg

20

<210> 24

<211> 93

<212> DNA

<213> Rat

<400> 24

AGCCGAGCCC ACCAGCACTC CATGGAGACA AGAACCCCTG ATATCAATCC TGCCTGGTAC 60

ACGGGCCGCG GGATCAGGCC TGTGGGCCGC TTC 93

<210> 25

<211> 96

<212> DNA

<213> Rat

<400> 25

AGCCGAGCCC ACCAGCACTC CATGGAGACA AGAACCCCTG ATATCAATCC TGCCTGGTAC 60

ACGGGCCGCG GGATCAGGCC TGTGGGCCGC TTCGGC 96

<210> 26

<211> 99

<212> DNA

<213> Rat

11/17

<400> 26

AGCCGAGCCC ACCAGCACTC CATGGAGACA AGAACCCCTG ATATCAATCC TGCTGGTAC 60

ACGGGGCCGCG GGATCAGGCC TGTGGGCCGC TTCGGCAGG 99

<210> 27

<211> 60

<212> DNA

<213> Rat

<400> 27

ACCCCTGATA TCAATCCTGC CTGGTACACCG GGCCGCGGGGA TCAGGCCTGT GGGCCGCTTC 60

<210> 28

<211> 63

<212> DNA

<213> Rat

<400> 28

ACCCCTGATA TCAATCCTGC CTGGTACACCG GGCCGCGGGGA TCAGGCCTGT GGGCCGCTTC 60

GGC 63

<210> 29

<211> 66

<212> DNA

<213> Rat

<400> 29

ACCCCTGATA TCAATCCTGC CTGGTACACCG GGCCGCGGGGA TCAGGCCTGT GGGCCGCTTC 60

GGCAGG 66

<210> 30

<211> 87

12/17

<212> PRT

<213> Human

<400> 30

Met Lys Val Leu Arg Ala Trp Leu Leu Cys Leu Leu Met Leu Gly Leu

1

5

10

15

Ala Leu Arg Gly Ala Ala Ser Arg Thr His Arg His Ser Met Glu Ile

20

25

30

Arg Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg

35

40

45

Pro Val Gly Arg Phe Gly Arg Arg Arg Ala Thr Leu Gly Asp Val Pro

50

55

60

Lys Pro Gly Leu Arg Pro Arg Leu Thr Cys Phe Pro Leu Glu Gly Gly

65

70

75

80

Ala Met Ser Ser Gln Asp Gly

85

<210> 31

<211> 261

<212> DNA

<213> Human

<400> 31

ATGAAGGTGC TGAGGGCCTG GCTCCTGTGC CTGCTGATGC TGGGCCTGGC CCTGCGGGGA 60

GCTGCAAGTC GTACCCATCG GCACCTCATG GAGATCCGCA CCCCTGACAT CAATCCTGCC 120

TGGTACGCCA GTCGCGGGAT CAGGCCTGTG GGCCGCTTCG GTCGGAGGAG GGCAACCCCTG 180

GGGGACGTCC CCAAGCCTGG CCTGCGACCC CGGCTGACCT GCTTCCCCCT GGAAGGCGGT 240

GCTATGTCGT CCCAGGATGG C 261

14/17

Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro Val Gly Arg Phe Gly

20

25

30

Arg

<210> 35

<211> 20

<212> PRT

<213> Human

<400> 35

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe

20

<210> 36

<211> 21

<212> PRT

<213> Human

<400> 36

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe Gly

20

<210> 37

<211> 22

<212> PRT

<213> Human

15/17

<400> 37

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro

1

5

10

15

Val Gly Arg Phe Gly Arg

20

<210> 38

<211> 93

<212> DNA

<213> Human

<400> 38

AGTCGTACCC ATCGGCACTC CATGGAGATC CGCACCCCTG ACATCAATCC TGCCTGGTAC 60

GCCAGTCGCG GGATCAGGCC TGTGGGCCGC TTC 93

<210> 39

<211> 96

<212> DNA

<213> Human

<400> 39

AGTCGTACCC ATCGGCACTC CATGGAGATC CGCACCCCTG ACATCAATCC TGCCTGGTAC 60

GCCAGTCGCG GGATCAGGCC TGTGGGCCGC TTCGGT 96

<210> 40

<211> 99

<212> DNA

<213> Human

<400> 40

AGTCGTACCC ATCGGCACTC CATGGAGATC CGCACCCCTG ACATCAATCC TGCCTGGTAC 60

16/17

GCCAGTCGCG GGATCAGGCC TGTGGGCCGC TTCCGGTCGG 99

<210> 41

<211> 60

<212> DNA

<213> Human

<400> 41

ACCCCTGACA TCAATCTGCTGGTACGCC AGTCGCGGGATCAGGCCTGT GGGCGCGCTTC 60

〈210〉 42

<211> 63

<212> DNA

<213> Human

<400> 42

ACCCCTGACA TCAATCCTGC CTGGTACGCC AGTCGGGGGA TCAGGCCCTGT GGGCCGCTTC 60

GGT 63

<210>

WPS OFFICE WORD PROCESSOR DOCUMENTATION 50

810/ 44

211/ 31

<Z1Z> PRI

<213> Unknown

〈220〉

221

<223> Xaa on the 3rd position means Thr or Ala, Xaa on the 5th position means Arg or Gln, Xaa on the 10th position means Ile or Thr, Xaa on the 21st position means Thr or Ala, Xaa on the 22nd position means Gly or Ser.

<400> 44

Ser Arg Xaa His Xaa His Ser Met Glu Xaa Arg Thr Pro Asp Ile Asp

Pro Ala Thr Tyr Xaa Xaa Arg Gly Ile Arg Pro Val Gly Arg Phe

20 25 30

〈210〉 45

<211> 20

〈212〉 PRT

<213> Unknown

〈220〉

〈221〉

<223> Xaa on the 10th position means Thr or Ala, Xaa on the 11th position means Gly or Ser.

<400> 45

Thr Pro Asp Ile Asn Pro Ala Trp Tyr Xaa Xaa Arg Gly Ile Arg Pro

15

Val Gly Arg Phe

20